Evidence map›Paper›PMID 36653238›Full record

ArticlePathology2023

Interobserver agreement in the histopathological classification of desmoplastic melanomas.

Cecilia Lezcano, Marianne Berwick, Li Luo, Raymond Barnhill, Lyn M Duncan, Pedram Gerami, Lori Lowe, Jane L Messina, Richard A Scolyer, Benjamin Wood and 3 more

Open access · greenAbstract read
In one paragraph

Article in Pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 3 countries.

Cecilia LezcanoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer, New York, NY, USA. Electronic address: lezcanom@mskcc.org.
Marianne BerwickDepartment of Internal Medicine, University of New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Li LuoDepartment of Internal Medicine, University of New Mexico Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA.
Raymond BarnhillDepartment of Translational Research, Institut Curie, Université de Paris UFR de Médecine, Paris, France.
Lyn M DuncanPathology Service, Dermatopathology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Pedram GeramiDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Lori LoweDepartments of Pathology and Dermatology, University of Michigan, Ann Arbor, MI, USA.
Jane L MessinaDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia.
Benjamin WoodDepartment of Anatomical Pathology, PathWest Laboratory Medicine, Perth, WA, Australia.
Iwei YehDepartments of Dermatology and Pathology, University of California San Francisco, San Francisco, CA, USA.
Artur ZembowiczDermatopathology Consultations LLC, Lahey Clinic and Tufts Medical School, Boston, MA, USA.
Klaus J BusamDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USHarvard University · USInstitut Curie · FRLahey Hospital and Medical Center · USMoffitt Cancer Center · USNorthwestern University · USPathwest Laboratory Medicine · AURoyal Prince Alfred Hospital · AUUniversity of California, San Francisco · USUniversity of Michigan–Ann Arbor · USUniversity of New Mexico · USUNM Comprehensive Cancer Center

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Desmoplastic melanoma is a subtype of melanoma characterised by amelanotic fusiform melanocytes dispersed in a collagenous stroma. Cell-poor and fibrous stroma-rich 'pure' variants have been distinguished from 'mixed' variants with areas of higher cell density and/or less desmoplastic stroma. This distinction is relevant because patients whose tumours display a pure phenotype have a lower risk for regional lymph node metastasis and distant recurrence. However, little is known about interobserver agreement among pathologists in the subclassification of desmoplastic melanoma. To address this issue, we conducted a study in which eleven dermatopathologists independently evaluated whole slide scanned images of excisions from 30 desmoplastic melanomas. The participating pathologists were asked to classify the tumours as pure or mixed. They were also asked to record the presence or absence of neurotropism and angiotropism. We found substantial interobserver agreement between the 11 dermatopathologists in the classification of tumours as pure versus mixed desmoplastic melanoma (kappa=0.64; p<0.0001). There was fair agreement between the 11 dermatopathologists in the evaluation of presence versus absence of neurotropism (kappa=0.26; p<0.0001), and slight agreement in the assessment of angiotropism (kappa=0.13; p<0.0001). The level of concordance in the subclassification of desmoplastic melanomas is encouraging for the acceptance of this prognostic parameter in the real-world practice of melanoma pathology.

Indexed as

MelanomaSkin NeoplasmsHumansObserver VariationPrognosisangiotropismDesmoplasticmelanomamixedneurotropismpure

Identifiers

PMID36653238
PMCPMC9974895
OpenAlexW4313406765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.